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To  understand  the  interactions  between  Notch1  and  Ikaros  in  the  evolution  of T cell  acute  lymphoblastic
leukemia  (T-ALL),  we  traced  the  evolution  of T-ALL  in mice  with  an inherited  Ikaros  mutation,  Ikzf1Plstc
which  inactivates  DNA  binding.  DNA-binding  Ikaros  repressed  Notch1  response  in transfected  cell lines
and in CD4+8+ (DP)  thymocytes  from  young  pre-leukemic  Ikzf1Plstc heterozygous  mice.  In  DP  thymocytes,
a  50–1000  fold  escalation  in mRNA  for Notch1  target  genes  Hes1  and  Dtx1  preceded  thymic  lymphoma  or
leukemia  and  was  closely  correlated  with  the  ﬁrst  detectable  differentiation  abnormalities,  loss  of  het-
erozygosity  (LOH)  eliminating  wild-type  Ikzf1, and  multiple  missense  and truncating  Notch1  mutations.
These  ﬁndings  illuminate  the  early  stages  of leukemogenesis  by  demonstrating  progressive  exaggera-
tion  of  Notch1  responsiveness  at the DP  thymocyte  stage  brought  about  by  multiple  mutations  acting  in
concert  upon  the  Notch1  pathway.
Crown Copyright ©  2011 Published by Elsevier Ltd. All rights reserved.
1. Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive
malignancy that has been associated with recurrent mutations in
a number of regulators of immature T cell differentiation, prolifer-
ation and survival including the genes encoding NOTCH1, LMO2,
HOXA11, LYL1, and TAL1 [1,2]. Notch1 is a receptor that under-
goes proteolytic cleavage to release its intracellular domain (ICN)
as a transcription regulator, which serves a key role in normal
thymocyte differentiation and is a frequent target of gain-of-
function mutations in T-ALL. Notch1 was identiﬁed at a recurrent
(7;9) (q34;34.3) translocation in T-ALL that fuses the 3′ portion of
NOTCH1 to the TCR- locus, leading to expression of constitutively
active forms of the Notch1 receptor (TAN1) [3].  This translocation
is present in <1% of human T-ALL but several studies have provided
evidence that Notch signalling in T cell leukemias and lymphomas
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Australia, 19 Mouat Street, Fremantle, WA  6959, Australia. Tel.: +61 8 94330236;
fax: +61 8 94330210.
E-mail address: gerard.hoyne@nd.edu.au (G.F. Hoyne).
1 Current address: Garvan Institute of of Medical Research Sydney.
2 Current address: School of Health Sciences, University of Notre Dame Australia,
Fremantle, WA,  Australia.
is often elevated even in the absence of genomic rearrangements
[4,5]. Somatic mutations that alter the NOTCH1 protein-coding
sequence have been found in more than 50% of human T-ALL with
diverse molecular subtypes [6].  These were found largely in the
extracellular heterodimerization (HD) domain, and truncating or
missense mutations in the C-terminal PEST domain that increase
stability of ICN [6–10]. The extent to which these individual NOTCH1
mutations in T-ALL confer a growth advantage or malignant trans-
formation is unclear. T-ALL have been described with multiple
NOTCH1 mutations in cis altering the HD and C-terminal domains,
and these have been shown to exaggerate NOTCH1 activity in tis-
sue culture in an additive manner and to function cooperatively for
leukemogenesis in vivo [7,9–12]. Some T-ALL NOTCH1 mutations
are sufﬁcient for promoting leukemogenesis while others are only
sufﬁcient for leukemogenesis in conjunction with other mutations,
raising the question of how many cooperating events precede the
ﬁrst outgrowth of a leukemic T cell clone [13–16].
Notch1 heterodimers comprising noncovalently associated
extracellular domain (NEC) and transmembrane domains (NTM)
are produced by the cleavage of pro-Notch1 by a furin-like pro-
tease during transit to the cell surface [17]. Activation of Notch
receptors occur upon binding of Notch Delta-Serrate-Lag2 (DSL)
ligands to the EGF repeat region of the NEC leading to cleavage
at S2 in the extracellular portion of NTM, creating a short-lived
membrane-bound NTM which is subject to mono-ubiquitination by
0145-2126/$ – see front matter. Crown Copyright ©  2011 Published by Elsevier Ltd. All rights reserved.
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FBXW7 to promote endocytosis and cleavage by -secretase at the
S3 site which releases the intracellular domain of NTM (ICN) [17].
The ICN then translocates into the nucleus and associates with the
transcription factor CSL or RBP-J and Mastermind-like 1-3 [17].
This complex activates transcription of Notch target genes includ-
ing Myc, PTEN/PI3K,  NFkB, Hes1, PreT  ˛ [18]. Not only mutations in
NOTCH1 itself can lead to leukemogenesis, cooperating mutations
in Notch target genes [19] and regulators (e.g. FBXW7 [20,21] and
Ikaros [22–24]) have been identiﬁed.
Mice with germline mutations that inactivate the tran-
scriptional regulator Ikaros (gene symbol Ikzf1) develop T-ALL
exclusively [23,25] and the resulting malignancies often have acti-
vating NOTCH1 mutations [6,23,24]. Ikzf1 somatic mutations are
also frequently found in combination with NOTCH1 mutations in
mouse retrovirus-promoted T-ALL [18] and in human B-ALL and
T-ALL [26,27]. Short, dominant negative forms of Ikaros gener-
ated by alternative splicing have also been found in human T-ALL
[28,29] although this has not been found in other T-ALL series [30].
Ikaros mRNA can undergo alternative splicing to yield a range of
isoforms some of which lack DNA binding domains (e.g. Ikzf1 4–9
isoforms) and so are unable to function as transcriptional regulators
but dimerize to act as dominant negative inhibitors of full length
Ikaros [31]. Ikaros mutations select for the expression of these short
dominant-interfering splice forms.
The relationship between Ikaros and Notch1 in thymocyte dif-
ferentiation and leukemogenesis is incompletely understood. Full
length Ikaros and RBP-J recognize the same DNA binding sequence
where Ikaros can inhibit RBP-J binding and stimulation of tran-
scription [22], but it is not known if Ikaros simply acts as a
competitive repressor of Notch-target genes. Animal models of T-
ALL provide a unique opportunity to study the cooperating events
needed for the initial outgrowth of leukemic T cells, but so far stud-
ies have focussed on the malignant phase when overt leukemia and
lymphadenopathy have ensued. Here, by analysing pre-leukemic
stages in the evolution of T-ALL in mice with an inactivating Ikaros
point mutation, we present evidence that Ikaros negatively reg-
ulates the Notch1 pathway at the DP thymocyte stage. The ﬁrst
detectable clonal outgrowth occurs selectively within the thy-
mus  around the DP stage of development, closely correlated with
somatic loss of the remaining wild-type Ikaros allele, a 10–1000
fold increase in mRNA from Notch-response genes, and accumu-
lation of somatic Notch1 mutations. These results indicate that
multiple mutations are needed and act cooperatively to activate
the Notch1 pathway before pre-leukemic thymocyte outgrowth
becomes detectable.
2. Methods
2.1. Animals
Ikzf1Plstc/+ mice were bred with C57BL/6 J background (Jackson Laboratory) and
maintained in the Australian Phenomics Facility and all procedures were approved
by  the Australian National University Animal Experimentation Ethics Committee.
2.2.  Flow cytometry
Lymphoid tissues were prepared as single cell suspensions in ice-cold PBS/10%
FCS and stained with ﬂuorochrome labelled monoclonal antibodies prior to FACS
analysis on a FACS Calibur ﬂow cytometer and the data analysed with FlowJo (Tree
Star) software.
2.3. Real time RT-PCR
DP thymocytes were sorted on FACSAria/Vantage (Becton Dickinson) and were
≥99% pure and total RNA was isolated using Trizol reagent (1 ml per 5–10 × 106 cells)
and  reverse transcribed to cDNA using SUPERSCRIPT First Strand cDNA Synthesis
kit  (Invitrogen). Samples were stored at −20 ◦C prior to use. Real-time RT-PCR was
performed using the TaqMan® Gene Expression Assays (Applied Biosystems) on
384-well plate platform on the ABI PRISM® 7900HT (Applied Biosystems). Relative
quantiﬁcation of mRNA level was performed using the comparative cycle threshold
(CT)  following the manufacturer’s instruction.
2.4. Analysis of Ikaros LOH
Genomic DNA samples were prepared from sorted cells from Ikzf1+/+ and
Ikzf1Plstc/+ mice and DNA was analysed for the loss of the wild type Ikaros allele by MS-
PCR [32] and Ampliﬂuor® PCR. End-point ﬂuorescence intensity for the PCR products
were analysed by FLUOstar OPTIMA (BMG Labtech). Positive controls included DNA
from Ikzf1+/+ and Ikzf1Plstc/Plstc embryos that was used to generate a standard curve.
Using the standard curve it was possible to calculate the percentage of the wild type
allele within the Ikzf1Plstc/+ samples.
2.5. Exonic sequencing for Notch 1 mutations
Mutation detection in exons 26, 27 and 34 of Notch1 was  performed via PCR
using primers speciﬁc for exons 26, 27 and 34 of Notch1 gene:
Exon 26 Forward (E26F) 5′ AGGGACACACTGGGAAACAG 3′
Exon 26 Reverse (E26R) 5′ GATGGGACTGAGTGCATCCT 3′
Exon 27 Forward (E27F) 5′ CCTCCAGCCCCTGATTACT 3′
Exon 27 Reverse (E27R) 5′ GTGCCATGTGTGTTCTCAGC 3′
Exon 34 Forward (E34F) 5′ TCCCTCATGTACCTCCTGTC 3′
Exon 34 Reverse (E34R) 5′ CCAACAGGGCTTGGGAAC 3′
PCR cycles included 97 ◦C for 3 min, 94 ◦C for 30 s, annealing at 59 ◦C for 60 s,
extension at 72 ◦C for 90 s. PCR products (5 l) were visualised on a 1.5% (w/v)
agarose gel with 5× DNA loading dye. The ampliﬁcation was repeated in triplicate.
The PCR products were puriﬁed using PureLinkTM PCR Puriﬁcation Kit (Invitrogen)
according to the manufacturer’s instructions. DNA was eluted in 50 l of water.
2.6.  Sequencing
PCR products were gel puriﬁed using PureLinkTM Quick Gel Extraction Kit (Invit-
rogen) according to the manufacturer’s instructions. DNA was dissolved into 50 l
of  water and the concentration determined by NanoDrop (ND1000). Addition of 3′
adenine to the ampliﬁed product was performed prior to cloning the product into
TOPO TA Cloning® System (Invitrogen) according to the manufacturer’s instruc-
tions. Plasmid DNA was transformed into One Shot® Chemically competent E. coli
cells (Invitrogen) with a 30 s heat shock at 42 ◦C followed by incubation at 37 ◦C
for  1 h. 10–50 l of each transformation was spread on a selective plate containing
100 g/ml ampicillin (Invitrogen) and X-gal (Invitrogen) and incubated overnight
at 37 ◦C. Approximately 12 white or light blue colonies per plate were picked and
cultured on 96-well growth block (Invitrogen) containing LB media with 100 g/ml
ampicillin. Puriﬁed plasmids of twelve clones per tumour sample were sequenced
in  the Biomedical Research Facility of John Curtin School of Medical Research.
2.7.  Luciferase assays
Hes1-Luciferase (Hes-1-Luc) [33] and Hey1-Luc reporter gene [34] used con-
tain  Hes1 promoter and Hey1 promoter regions, respectively. Each promoter region
contains two  RBP-Jk binding sites. NIH3T3 cells were grown in DMEM containing
10%  FCS. Transfections were performed in C2C12 cells using LipofectAMINE and Plus
reagent (Invitrogen) according to the manufacturer’s instructions. Luciferase assay
transfections in 12-well trays contained 14 ng of CMV-Renilla plasmid, 350 ng of
Hes1-Luc or Hey1-Luc and 350 ng of each expression plasmid (pCMX-ICN, pCMX-
Ikzf1,  pCMX-Ikzf1Plstc) or pCAT-CMX control plasmid. Fireﬂy and Renilla luciferase
activities were assayed using the Dual-luciferase reporter system (Promega) and
measured on a FLUOstar Optima Luminometer (BMG). Fireﬂy luciferase counts were
normalised against Renilla luciferase counts to account for differences in transfec-
tion efﬁciency.
3. Results
3.1. Expanded populations of CD8+CD4low TCRˇhi thymocytes
with LOH mutations
To identify the early steps leading to T-ALL, we systematically
analysed the thymi of a large cohort of Ikzf1Plstc/+ mice during the
pre-leukemic phase between 4 and 12 weeks of age when ≥90% of
animals remain disease free (Fig. 1A). Up to 6 weeks of age there
was no difference in CD4 or CD8 differentiation in the thymus of
wild type and Ikzf1Plstc/+ mice (data not shown) but by 8–12 weeks
of age most Ikzf1Plstc/+ mice exhibited a larger shoulder of CD8+
CD4low cells below the normal DP thymocyte population despite
normal or only slightly elevated numbers of thymocytes (Fig. 1B).
These abnormal CD8+ CD4low cells in the thymus were typically
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Fig. 1. Evolution of leukemia and pre-leukemic abnormalities within the thymus. (A) Percentage of healthy Ikzf1+/+ and Ikzf1Plstc/+ mice (n = 49) at the indicated ages. Animals
were  euthanased when they developed clinical symptoms of leukemia or thymic lymphoma including cachexia, malaise, and laboured breathing. (B) Flow cytometric staining
for  CD4 and CD8 on thymocytes and splenocytes from Ikzf1+/+ (far left panel in each row) or Ikzf1Plstc/+ mice analysed prior to clinical symptoms of leukemia at the indicated
ages.  Numbers above each plot show the mouse number, and the number of cells in the thymus (T) and spleen (S). Samples indicated in red correspond to those in Fig. 2B
with  <5%, 5–15%, or 15–25% wild-type Ikzf1 DNA in DP cells, respectively.
TCRhi CD5hi, comparable to post-positive selection CD8 SP cells in
normal thymi, except that they were CD69 negative whereas most
normal CD8 SP cells are CD69+ (Supplemental Fig. 1). The DP pop-
ulation itself also exhibited increased expression of TCR, CD3 and
CD5 in these individuals (Supplemental Fig. 1). Staining for spe-
ciﬁc V regions showed monoclonal or oligoclonal expansion of
TCR-V cells (e.g. TCR-V5hi or TCR-V8.3hi cells) in the thymus
of a subset of animals aged 10–12 weeks, but these expanded T
cell clones were not detected in the peripheral lymphoid tissues at
this age (Supplemental Fig. 2). In the majority of 8- to 12-week-old
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mice with these early stage abnormalities, the number and phe-
notype of peripheral lymphocytes was normal, and hence these
animals are referred to as “pre-leukemic”. However a minority of
mice at 12 weeks of age had low frequencies of abnormal DP cells
in the thymus and spleen (e.g. mouse G17.2 in Fig. 1B). Flow cyto-
metric analysis of the peripheral DP cells in the spleen revealed
that they shared an identical cellular phenotype that were typi-
cally TCRhi CD5hi. The similar phenotype between thymocytes and
splenocytes suggests that the peripheral DP phenotype cells were
thymic derived and did not arise spontaneously in the periphery
(Supplemental Figs. 3 and 4).
The indication above that abnormal leukemic clones evolve
initially within the thymus was investigated further by testing
thymocytes for somatic Ikzf1 loss of heterozygosity (LOH). DP thy-
mocytes were sorted from individual mice in a 6- to 12-week-old
cohort, genomic DNA prepared, and a quantitative ﬂuorescent SNP
assay used to measure the amount of Ikzf1+/+ and Ikzf1Plstc/+ DNA
in each sample (Fig. 2A). This revealed that DP thymocytes in the
majority of the Ikzf1Plstc/+ mice retained the wild-type Ikzf1 allele in
heterozygous state up to 6 weeks of age but this allele accounted
for less than 25% of Ikzf1 DNA or became undetectable in a progres-
sively increasing proportion of 8- to 12-week-old mice (Fig. 2B). The
extent of Ikzf1 LOH in DP cells of individual mice correlated with
the extent of ﬂow cytometric abnormalities (Fig. 2C). Somatic loss of
wild-type Ikaros in DP thymocytes occurred in animals that did not
have thymic lymphoma nor peripheral leukemia. For example, the
wild type Ikaros allele was less than 10% or undetectable in DP cells
from G17.23 and G16.62, respectively (Fig. 2B), yet total thymocyte
numbers in these individuals were only twice normal (Fig. 1B) and
the expanded thymic clone of TCR-V8.3+ or TCR-V5+ T cells was
undetectable in peripheral tissues (Supplemental Fig. 2).
3.2. Somatic loss of LOH correlates with a large increase in Notch
target gene expression in DP thymocytes
In parallel with the ﬂow cytometric and LOH analyses of the
cohort of Ikzf1Plstc/+ mice above, mRNA was prepared from the same
samples of sorted DP cells and used to measure expression of Notch
target genes and other developmental genes by real-time PCR. We
focussed ﬁrst on Hes1 which was of particular functional relevance
because its product is known to suppress CD4 expression [35] and
hence might explain the CD8+ CD4low phenotype of the earliest
detectable abnormal thymocytes. Compared to control DP cells
sorted in parallel from wild-type mice, Hes1 mRNA was  modestly
elevated in 6- to 8-week-old mice with no evidence of an abnormal
CD4–CD8 proﬁle, but became dramatically increased to 100–1000
times the normal DP cell levels in DP cells from 10- to 12-week-old
Ikzf1Plstc/+mice (Fig. 3A and Supplemental Fig. 5). Increased Hes1
mRNA was inversely correlated with loss of wild-type Ikzf1 in DP
thymocytes (Fig. 3A, r = −0.77), and with increased percentage of
CD8+ CD4low thymocytes measured ﬂow cytometrically (Fig. 3B,
r = 0.82). Thus, while the heterozygous Ikaros point mutation did
not result in any appreciable increase in expression of the Notch1
target gene Hes1 in DP thymocytes that retained 50% wild-type
Ikzf1 DNA, the proportion of thymocytes that had lost the wild-
type allele was closely correlated with dramatically exaggerated
Hes1 expression.
Ikaros LOH in DP thymocytes was closely correlated (r = −0.79)
with a 10–100 fold increase in Dtx1 expression (Fig. 3C). Expression
of pre-Ta,  which is both developmentally regulated and Notch1 reg-
ulated [36], was increased in most samples with LOH but less well
correlated (Fig. 3C, r = −0.58). There was little correlation between
Ikzf1 LOH and mRNA expression of Rag1 gene, which is not known
to be a direct Notch1 target (Fig. 3C, r = −0.24).
The evidence above that the remaining wild type Ikaros allele
in Ikzf1Plstc/+ DP cells served as a critical negative regulator for
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Fig. 2. Correlation between loss of Ikaros heterozygosity and appearance of abnor-
mal  ﬂow cytometric subsets in thymi of Ikzf1Plstc/+ mice. (A) Quantitative ﬂuorescent
SNP assay to measure the percentage of wild-type and Ikzf1Plstc alleles. DNA stan-
dards were prepared by mixing different proportions of DNA from Ikzf1+/+ and
Ikzf1Plstc/Plstc embryos. (B) Percent wild-type Ikzf1 DNA in sorted DP cells from indi-
vidual Ikzf1+/+ and Ikzf1Plstc/+ mice at the indicated weeks of age. (Red) <5% wild type
Ikzf1 remaining, (blue) 5–15% wild type Ikzf1 remaining, (purple) 15–25% wild type
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metric evidence of abnormal thymocyte differentiation as reﬂected by the ratio of
CD8+ CD4low cells to DP cells. Pearson’s correlation coefﬁcient (r); P value depicts
the  signiﬁcance of linear regression as calculated by Fisher’s exact test on GraphPad
Prism. Age of mice indicated by colour: black, 4 weeks; green, 6 weeks; purple, 8
weeks; blue, 10 weeks; red, 12 weeks.
Notch1-induced gene expression was corroborated in cell lines
bearing luciferase reporters controlled by promoter elements from
two different Notch target genes, Hes1 and Hey1. Co-transfection
of DNA encoding the wild-type Ikaros full-length isoform (Ik1)
inhibited transcriptional induction by DNA encoding the intracel-
lular domain of Notch1 (ICN). By contrast, co-transfection of DNA
encoding Ik1 bearing the H191R mutation was  unable to repress
activation of the Hes1 or Hey1 reporter constructs (Fig. 4). These
results are consistent with other evidence that Ikaros negatively
regulates Notch1 target gene expression [22,23,35,37–39]. Since
the H191R point mutation disrupts DNA binding but leaves expres-
sion of otherwise normal full-length Ikaros isoforms in DP  cells,
these results collectively establish that the inhibitory effect of
Ikaros on transcription of Notch1 targets in DP cells requires the
DNA recognition domain and cannot be supplied through other
parts of the full-length Ikaros protein.
Please cite this article in press as: Sontani Y, et al. Cooperation between somatic Ikaros and Notch1 mutations at the inception of T-ALL. Leuk Res
(2011),  doi:10.1016/j.leukres.2011.07.024
ARTICLE IN PRESSG ModelLR-4355; No. of Pages 8
Y. Sontani et al. / Leukemia Research xxx (2011) xxx– xxx 5
A
D
N
A
r = -0.77
40
50
60
G17.57
G17.65
G17.58
G17.15
G17.13
G17.33
G17.14
G17.31
%
 w
ild
 ty
pe
 Ik
zf
1
D
10
20
30 G17.60
G17.59
G17.1
G17.3
G15.30 G17.19
G15.28 G15.31
G17.25
G17.24
G17.23
Relave Hes 1 mR NA expression  (Lo g10)
0
-1 0 1 2 3 4
G17.2
G15.32 G17.27G16.65 G16.62
B
35
40 r=0.82
1 4
1.6 r = 0.70
P
%
 C
D
8+
CD
4l
ow
ce
lls
 
0
5
10
15
20
25
30 P<0.000 1
0
0.2
0.4
0.6
0.8
1.0
1.2
.
P=0.000 1
Ra
o
 C
D
8+
CD
4l
ow
/D
P
C
-1 0 1 2 3 4
Relave Hes 1 mR NA expression  (Lo g10)
Dtx1
r= -0.79
30
40
50
60
40
50
60
r= -0.45
Ikzf1
-1 0 1 2 3 4
R
10
20
1 2
0
-1 30 4 5
pTαRag1
0
10
20
30
0 2 4 6 8 10
e 
 
(Log10)
10
20
30
40
50
60
r= -0.58
10
20
30
40
50
60
r= -0.24 
0
0 2 4 6 8 10
0
0 2 4 6 8 10 12
Relave mR NA expression
Ik
zf
1
D
N
A
%
 w
ild
ty
pe
Fig. 3. Correlation between Ikzf1 LOH and increased mRNA for Notch target genes
in  DP thymocytes of Ikzf1Plstc/+ mice. (A) Relationship between % wild-type Ikzf1 DNA
and mRNA from the Notch target gene Hes1 in DP cells. Individual mouse numbers
are shown, colour-coded by age: black, 4 weeks; green, 6 weeks; purple, 8 weeks;
blue, 10 weeks; red, 12 weeks. r represents Pearson’s correlation coefﬁcient. (B)
Relationship between ﬂow cytometric evidence of abnormal thymocyte differenti-
ation and Hes1 mRNA in DP cells. r represents Pearson’s correlation coefﬁcient and P
value depicts the signiﬁcance of linear regression as calculated by Fisher’s exact test.
(C). Relationship between % wild-type Ikzf1 DNA and mRNA for Dtx1, Ikzf1, Rag1, and
pre-T˛.  Individual mouse numbers are shown, colour-coded by age: black, 4 weeks;
green, 6 weeks; purple, 8 weeks; blue, 10 weeks; red, 12 weeks. r represents Pear-
son’s correlation coefﬁcient. The x axis for Dtx1 expression in DP cells is represented
as Log10 values while all other graphs are shown on a linear scale.
Hes1-reporter Hey1-reporter
5
6
7
e 
ac
tiv
ity ** **
** **
0
1
2
3
4
R
el
at
iv
e 
Lu
ci
fe
ra
se
R
CAT:
N1IC:
Ikaros:
+ + + + + +
+ + +
wt mu t wt mut
+ + + + + +
+ + +
wt mu t wt mut
Fig. 4. Ikaros H191R encoded by Ikzf1Plstc cannot repress NotchIC-induced transcrip-
tion. The Hes1 or Hey1 promoter was  coupled to a luciferase reporter (Hes1-luc,
Hey1-luc)  that was  stably transfected into C2C12 cells. The C2C12 cells were tran-
siently transfected with plasmids encoding constitutively active Notch1 receptor
(ICN) with or without plasmids containing wild type Ikzf1 or Ikzf1Plstc H191R allele.
Error bars represent the standard deviation of the mean luciferase activity. Data is
shown as mean ± SD (**p < 0.001).
3.3. Notch1 missense and PEST truncation mutations accompany
Ikaros LOH at the earliest detectable stages of abnormal
thymopoiesis
In parallel with analysing Ikaros LOH and Notch1-target gene
expression in the cohort of pre-leukemic Ikzf1Plstc/+ mice, we PCR
ampliﬁed, cloned and sequenced Notch1 exons 26 and 27 encoding
the HD domain and exon 34 encoding the C-terminal PEST domain
from genomic DNA of the sorted DP cells (Table 1 and Supplemental
Figs. 6 and 7). In DP cells from 12 Ikzf1Plstc/+ mice aged between 4
and 8 weeks of age with no thymic ﬂow cytometric abnormali-
ties, 3 independent insertion/deletions were detected in exon 34
that truncate ICN (2 in 4-week-old mouse G17.59; 1 in 8-week-old
G17.1). These two  animals also had little or no increase in Hes1
mRNA in DP cells and retained a wild-type Ikzf1 allele in the major-
ity of cells (Fig. 3A). ICN truncating mutations were found at a higher
rate (9 mutations in 7 of 11 mice tested) in DP cells from mice
with ﬂow cytometrically abnormal thymocytes, despite many lack-
ing detectable leukemia (e.g. G17.23). Of the ﬂow cytometrically
abnormal samples with ICN-truncating mutations, all that were
tested also had complete or near-complete Ikzf1 LOH and 50–1000
fold increased Hes1 mRNA (Fig. 3A, samples G17.2, G17.23, G17.27,
G16.64, G15.32). No insertion/deletion truncating mutations were
found in exons 26 and 27. Missense mutations in Notch1 exons
26, 27 and 34 were detected in DP cells from thymi with normal
or abnormal ﬂow cytometry (Table 1, Supplemental Figs. 6 and
7), including several such as L1668P (L1679P in human NOTCH1)
that are repeatedly found in human T-ALL and are well estab-
lished to destabilize the HD domain negative regulatory region
[10]. While a comparable rate of nucleotide substitutions was
found in thymic samples with normal or abnormal ﬂow cytometry,
the replacement-to-silent ratio was consistent with selection for
replacements in DP cells from thymi with abnormal ﬂow cytomet-
ric proﬁles (R/S = 6) whereas there was no evidence for selection in
samples without ﬂow cytometric abnormalities (R/S = 1.4). Because
the different exons were ampliﬁed separately, we cannot deter-
mine if the HD missense mutations were combined in cis with
ICN truncating mutations as has been observed in human T-ALL.
Thus, while potentially activating Notch1 mutations precede the
ﬁrst ﬂow cytometrically detectable thymocyte abnormalities in
preleukemic animals, the transition to detectably abnormal thy-
mopoiesis is accompanied by strong selection for activating Notch1
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Table 1
Number of mutation exons 26, 27 and 34 of the Notch1 gene observed in individual clones from Ikzf1Plstc/+ mice.
DP sample Thymus ﬂow
cytometry
Exon 34
#clones seq’d
Exon 34 truncating
mutations
Exon 34
mutations
Exon 26
#clones seq’d
Exon 26
mutations
Exon 27
#clones seq’d
Exon 27
mutations
Replacement
mutations
Silent
mutations
G17.55 Normal 7 0 1 1 0 12 0 0 1
G17.57 Normal 10 0 5 4 0 11 0 3 2
G17.59 Normal 11 1 5 1 0 10 0 3 2
G18.13  Normal 5 0 0 2 0 10 0 0 0
G18.14 Normal 9 0 0 4 1 5 1 1 1
G18.15  Normal 6 0 0 7 0 11 0 0 0
G18.31 Normal 9 0 0 6 1 5 0 0 1
G18.33  Normal 0 0 0 2 0 11 0 0 0
G17.1 Normal 11 1 2 6 3 1 2 4 3
G17.3 Normal 11 0 5 6 2 9 0 4 3
G17.19 Normal 12 0 2 9 2 8 0 3 1
G17.25 Normal 12 0 3 11 1 8 0 3 1
Totals 103 23 59 10 101 3 21 15
Sequenced nt 148,320 23,541 16,362
Mutations per 100,000 nt sequenced 16 42 18
Total  exonic mutations per 100,000 nt 25
Replacement/silent ratio 1.4
G17.2  Abnormal 11 1 4 7 0 5 1 4 1
G17.23 Abnormal 11 1 2 8 0 6 0 2 0
G17.24  Abnormal 8 0 1 10 1 7 0 2 0
G17.27  Abnormal 7 1 2 11 1 4 0 2 1
G16.62  Abnormal 1 0 0 11 0 7 0 0 0
G16.64 Abnormal 5 1 2 10 0 6 0 2 0
G16.65  Abnormal 0 0 0 9 1 6 1 1 1
G20.109 Abnormal 7 0 1 1 1 4 0 2 0
G20.91 Abnormal 7 1 4 1 0 7 0 4 0
G20.92  Abnormal 4 0 1 2 0 7 1 2 0
G20.47  Abnormal 0 0 0 2 0 6 1 1 0
G20.58  Abnormal 5 2 2 5 1 7 0 2 1
G20.29 Abnormal 0 0 1 2 1 6 1 3 0
Totals  66 20 79 6 78 5 27 4
Sequenced nt 103,680 31,521 12,636
Mutations per 100,000 nt sequenced 19 19 40
Total  exonic mutations per 100,000 nt 26
Replacement/silent ratio 6.75
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somatic mutations in addition to somatic mutations that eliminate
the remaining wild-type Ikaros allele.
4. Discussion
In this study we sought to understand the relationship between
Ikaros and Notch1 signalling for normal T cell differentiation and
the initial stages of neoplastic growth. We  conﬁrm and extend
earlier evidence [22,23] that Ikaros acts as a critical inhibitor of
Notch1-induced gene expression at the DP thymocyte differen-
tiation stage and we show that somatic Ikzf1 LOH mutations in
thymocytes are accompanied by a dramatic escalation in expres-
sion of Notch1 target genes. Potentially activating mutations in
Notch1 itself can be detected even earlier, and these are strongly
enriched concurrent with Ikzf1 LOH and ﬂow cytometric abnormal-
ities in thymocyte growth or differentiation. These results extend
the view emerging from human T-ALL and associated experimental
studies [10,11] that multiple mutations acting in concert upon the
Notch pathway are needed to exaggerate Notch1 transcriptional
activity above a threshold that can promote neoplastic T cell growth
in vivo.
The overriding view of Ikaros function in T cell development
is that it functions to repress Notch signalling in DP cells due
to Ikaros’ ability to bind to 5′ regulatory elements within the
Hes1 and Dtx1 promoters [23,24,35].  Somatic mutations in the
HD domain of Notch 1 occur in ∼40–50% of T-ALLs and Notch
receptors that bear HD mutations can be expressed at the cell
surface and are still responsive to ligands, but they can also sig-
nal in a ligand independent manner [10,40]. The cell autonomous
activation of Notch signals could contribute to the induction or
the progression of T-ALL in several ways. We  observed HD muta-
tions in Ikzf1Plstc/+ mice as young as 4 weeks of age when T
cell development was normal, indicating that individual somat-
ically acquired Notch 1 mutations are not sufﬁcient to drive
T cell leukemia or disrupt thymopoiesis. Similar HD mutations
and mutations that lead to truncation of the Notch1 intracellu-
lar domain have been identiﬁed in other animal models bearing
Ikaros mutations suggesting that Notch1 is a frequent target of
mutations in these T cell derived tumors [23,24]. This is consis-
tent with the conclusions from retroviral introduction of Notch1
HD or truncating mutations into bone marrow reconstituted mice
[11].
The systematic analysis here of young animals that had few
or no abnormal T cells circulating in their spleen, lymph nodes
or bone marrow provides a view of the early evolution of T-ALL.
Previous studies of other Ikaros mutant animals have focussed on
the malignant phase when overt leukemia and lymphadenopa-
thy has ensued. LOH of the remaining wild type Ikzf1 allele was
observed and was suggested to be a late stage event in progres-
sion to T cell leukemia when large numbers of abnormal T cells
accumulated extrathymically in peripheral tissues [23–25].  How-
ever, in the current study Ikzf1 LOH was detected in Ikzf1Plstc/+ mice
between 6 and 8 weeks of age and this was strongly correlated
with a 100–1000 fold increase in Notch target gene expression and
the ﬁrst detectably ﬂow cytometric changes in thymocyte develop-
ment. At this stage, abnormal T cells were only detectable within
the thymus and not in the peripheral tissues. The most signiﬁcant
changes occurred in Hes1 and Dtx1 expression and these two tar-
get genes were also observed to be increased in studies of tumors
derived from Ikzf1Plstc/+ and IkarosL/L mice [23,24].  This contrasts
to the report by Mantha et al. who did not detect LOH of the wild
type allele of Ikzf1 in Ikzf1Plstc/+ mice before 12 weeks of age. Dra-
matically exaggerated Notch signalling in DP cells can arrest their
development [41] and may  explain why leukemias in Ikzf1Plstc/+
mice are generally of a DP or CD8+CD4int cell immature T cell
phenotype.
A cooperative role between Ikaros and Notch mutations and
pre-TCR signalling in T cell transformation and leukemia has been
highlighted [6,8,10]. Consistent with these results T-ALL is greatly
suppressed in Rag1-deﬁcient Ikzf1Plstc/+ mice where the TCR- chain
cannot be rearranged to assemble pre-TCR (unpublished data).
Notch1 and Notch3 activate pTa gene expression cells in a way that
is repressed by DNA-binding Ikaros isoforms [23,42]. Indeed, Ikzf1
LOH was  correlated with a 2–8 fold increase in pTa mRNA in DP
cells from Ikzf1Plstc/+ mice similar to that reported by Dumortier
et al. in tumors derived from IkarosL/L mice [23]. Notch1 induces
Notch3, and constitutively active Notch3 signalling alters Ikzf1
mRNA splicing to yield short non-DNA binding isoforms that relieve
Ikaros repression of Notch-induced pTa [42]. Thus there appear to
be two alternative pathways for somatically inactivating Ikaros’
repressive function in the evolution of T-ALL, either by somatic
loss of the wild-type Ikzf1 as occur here or by accumulation of
other mutations in NOTCH1, FBXW7, etc. that exaggerate NOTCH
signalling sufﬁciently to suppress full-length Ikaros mRNA and
protein.
The data presented here emphasize the need for multiple muta-
tions dysregulating Notch-signalling during the inception of T cell
leukemia in vivo. The earliest stages of abnormal thymic differen-
tiation were accompanied by somatic mutations in the HD and
PEST domains of the Notch1 gene that are known to exaggerate
ICN production, induce expression of Myc  [11] and Cyclin-D1 (26)
and inhibit the expression of tumour suppressor genes (e.g. p19ARF
– p53) or growth regulators such as p27kip1 and Nur77 [43]. Loss
of DNA-binding Ikaros appears to be a critical collaborator in this
inception phase, relieving the ICN-RBPJk-MAML transcriptional
complex from repressive effects of Ikaros [23,42] and correlating
closely with a dramatic increase in Notch target gene expres-
sion in pre-leukemic DP cells. This multi-step increase in Notch
signalling may  be required to achieve a threshold for inducing
Myc, repressing p19Arf, and initiating neoplastic DP cell growth
in vivo, as suggested by Chiang et al. [11]. Mutant Notch1 recep-
tors can still bind and respond to Notch ligands and this may be
important in the engraftment of the mutant cells into the bone
marrow and secondary lymphoid tissues [44]. Given that multi-
ple steps appear necessary for the initiation of leukemic growth,
T-ALL cells may  be particularly sensitive to agents that target
even one of these steps to lower Notch signalling by intermediate
amounts.
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